Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
NCT ID: NCT00236093
Last Updated: 2014-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
NCT00236041
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
NCT00236145
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
NCT00496392
Safety of Fentanyl TAIFUN Treatment
NCT00822614
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
NCT00842829
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient completed participation in ACTIQ double blind study in compliance with the protocol
* Written informed consent of the parent or legal guardian and patient assent, when appropriate, is obtained (lack of assent cannot be overturned)
* The child is aged 3 to under 16 years (at the time of enrollment into the ACTIQ double blind study) and continues to weight at least 15kg
* The child must continue using ATC opioid therapy for pain associated with cancer, sickle cell disease, or severe burns and be opioid-tolerant. Opioid tolerant patients are defined as patients who have taken at least 1 mg/kg/day or 40mg/day or more of oral morphine (or an equianalgesic dosage of another opioid) or at least 25 mcg/hour of transdermal fentanyl for at least 7 days. (ATC opioid therapy may be administered as patient controlled analgesia \[PCA\]).
* The child must be experiencing episodes of BTP (defined as transient flares of pain that require a bolus of medication as treatment) as follows:
* Patients with cancer must be experiencing an average of at least 1 BTP episode a day
* Patients with non-cancer related pain must be experiencing an average of 2 BTP episodes a day
* Girls who are postmenarch or sexually active must have a negative urine pregnancy test before entry into the study, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implanted, or injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence
* The child, in the opinion of the investigator, is able to administer ACTIQ treatment effectively (ie, adequately moving the unit around the mouth and sucking not biting the unit)
* The child may be an inpatient or outpatient
Exclusion Criteria
* The child has pain uncontrolled by therapy, as determined by the investigator, that could adversely impact the safety of the patient or could be compromised by treatment with ACTIQ.
* The child has known or suspected hypersensitivities/allergies or other contraindications to any ACTIQ component
* The child has received monoamine oxidase inhibitors (MAOIs) within 14 days of the first dose of study drug administration
* The child has moderate to severe oral mucositis
* The child has a neuromuscular disease, significant renal impairment, or significant hepatic impairment as determined by the investigator
* The child has any other medical condition or is receiving concomitant medication/therapy that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise data collection
* The child is receiving any experimental drug/therapy. NOTE: Children may not be participating concurrently in another study when the other study requires experimental drug therapy.
* The child is receiving any other treatment that, in the opinion of the investigator, could interfere with the pain response
* A female patient of childbearing potential, is pregnant, or is lactating (any girl becoming pregnant during the study will be withdrawn from the study)
* The child has, in the opinion of the investigator, a development delay that would interfere with the use of ACTIQ therapy
3 Years
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cephalon
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Messina
Role: STUDY_DIRECTOR
Cephalon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of Arkansas
Little Rock, Arkansas, United States
Childrens Hospital of Orange
Orange, California, United States
Lucille Packard Childresns Hospital
Palo Alto, California, United States
Connecticut Childrens Medical
Hartford, Connecticut, United States
Childrens National Medical Center
Washington D.C., District of Columbia, United States
Nemours Childrens Clinc
Jacksonville, Florida, United States
St. Joseph's Childrens Hopsital
Tampa, Florida, United States
Kapi'olani Medical Center
Honolulu, Hawaii, United States
University Hospitals of Iowa
Iowa City, Iowa, United States
David Center for Childrens Pain and Palliative Care
Hackensack, New Jersey, United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
University of New Mexico
Albuquerque, New Mexico, United States
Scottish Rite Children's Medical Center
Syracuse, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Children's Hospital at Montefiore
The Bronx, New York, United States
Duke University Hospital
Durham, North Carolina, United States
Akron Children's Hospital
Akron, Ohio, United States
Tod Childrens Hospital
Youngstown, Ohio, United States
Milton S Hershey Medical Center
Hershey, Pennsylvania, United States
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Children's Cancer and Blood Disorders Center
San Antonio, Texas, United States
Methodist Hospital
San Antonio, Texas, United States
Sacred Heart Medical Center
Spokane, Washington, United States
West Virginia Univeristy
Morgantown, West Virginia, United States
Childrens Hospital of Wisconsin
Milwaukee, Wisconsin, United States
Iwk Health Center
Halifax, Nova Scotia, Canada
San Jorge Childrens Medical
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C8278/2022/BP/US-CA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.